Evidence map›Paper›PMID 40261049›Full record

ArticleAntimicrobial agents and chemotherapy2025

Efficacy of novel regimens targeting oxidative phosphorylation in

Dongshuo Li, Liang Li, Ye Zhang, Kai Cheng, Wenwen Liang, Eric Nuermberger, Xianglong Qi, Lei Fu, Bin Wang, Chenxia Yan and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Dongshuo Li *Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Liang Li *Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Ye Zhang *Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Kai ChengBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Wenwen LiangBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Eric NuermbergerDepartment of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.ORCID 0000-0003-1440-9889
Xianglong QiBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Lei FuBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Bin WangBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Chenxia YanBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Rui XuBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
Yu LuBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID 0000-0002-9038-1884
Jian XuBeijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.ORCID 0000-0001-6100-0547

Funding

Beijing Hospital Authority DFL20221402Beijing Municipal Health Commission G2024-2-006National Natural Science Foundation of China 81803588Natural Science Foundation of Beijing Municipality 7202029
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antitubercular AgentsMycobacterium tuberculosisOxidative PhosphorylationAdamantaneAnimalsClofazimineDiarylquinolinesDrug Therapy, CombinationEthylenediaminesFemaleImidazolesMiceMice, Inbred BALB CMicrobial Sensitivity TestsPiperidinesPyrazinamideAdamantaneAntitubercular AgentsbedaquilineClofazimineDiarylquinolinesEthylenediaminesImidazolesN-geranyl-N'-(2-adamantyl)ethane-1,2-diaminePiperidinesPyrazinamidePyridinestelacebecbedaquilineclofazimineelectron transport chainmurine modelMycobacterium tuberculosisoxidative phosphorylationpyrazinamidetelacebec

Identifiers

PMID40261049
PMCPMC12135524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.